# alopecia areata FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/alopecia-areata

> 10 upcoming FDA catalysts in alopecia areata: LY4005130 (LLY) on June 2027 (primary completion); LY4005130 (LLY) on Jun to Sep 2027 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on Mar to Jun 2028 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on March 2028 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q2 2025 | [AQST-108 trial start](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "The Company remains on track to begin its Phase 2a clinical trial of AQST-108 in patients with AA in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm)) |
| September 24, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Alopecia Areata | withdrawn | "NCT06444451 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06444451)) |
| Q4 2025 | [AQST-108 NDA/BLA submission](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "Aquestive continues to work toward its anticipated submission of an Investigational New Drug Application for AQST-108 for the treatment of alopecia areata (AA) to the FDA in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| November 26, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Alopecia Areata | completed | "NCT06340360 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-26 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340360)) |
| 1H 2026 | [AQST-108 trial start](https://sec-api.dev/pdufa/aqst-108) | AQST | alopecia areata | scheduled | "Aquestive plans to initiate its Phase 2a clinical trial of AQST-108, a topical gel formulation for the treatment of alopecia areata (AA), in the first half of 2026, after the launch of Anaphylm." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025024659/q12025-ex991earningsrelease.htm)) |
| June 2026 | [Bempikibart (adx-914) primary completion](https://sec-api.dev/pdufa/bempikibart-adx-914) | QTTB | Alopecia Areata | delayed | "NCT06018428 (A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06 (ESTIMATED); Lead Sponsor Q32 Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06018428)) |
| June 2027 | [LY4005130 primary completion](https://sec-api.dev/pdufa/ly4005130) | LLY | Alopecia Areata | scheduled | "NCT07533006 (A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533006)) |
| Jun to Sep 2027 | [LY4005130 topline data readout](https://sec-api.dev/pdufa/ly4005130) | LLY | Alopecia Areata | scheduled | "NCT07533006 (A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07533006)) |
| Mar to Jun 2028 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873945)) |
| March 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873945)) |
| Apr to Jul 2028 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733765)) |
| April 2028 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Alopecia Areata | scheduled | "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733765)) |
| February 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023302)) |
| Feb to May 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023302)) |
| April 2030 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012240)) |
| Apr to Jul 2030 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012240)) |

## Drugs

- [AQST-108](https://sec-api.dev/pdufa/aqst-108) (AQST)
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin) (NKTR)
- [Bempikibart (adx-914)](https://sec-api.dev/pdufa/bempikibart-adx-914) (QTTB)
- [LY4005130](https://sec-api.dev/pdufa/ly4005130) (LLY)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/alopecia-areata.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "alopecia areata FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/alopecia-areata

```bibtex
@misc{secapidev_indications_alopecia_areata_20261116,
  title        = {alopecia areata FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/alopecia-areata}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_alopecia_areata_20261116","title":"alopecia areata FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/alopecia-areata","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
